Evidence map›Paper›PMID 36851144›Full record

ArticleVaccines2023

Evaluating the Adverse Events Associated with Three Doses of the COVID-19 Vaccination in Adults in the Western Region of Saudi Arabia: A Cross-Sectional Study.

Hamzah J Aldali, Jehad A Aldali, Badi A Alotaibi, Glowi A Alasiri, Aroob M Alromih, Emadeldin M Elsokkary, Ali Z Aldali, Abdullah Almeziny

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Hamzah J AldaliCellular and Molecular Medicine, College of Biomedical Science, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0001-8588-0921
Jehad A Aldali0921 Department of Pathology, Faculty of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.
Badi A AlotaibiDepartment of Clinical Laboratory Sciences, Collage of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia.ORCID 0000-0003-4540-1732
Glowi A AlasiriDepartment of Biochemistry, College of Medicine Organization Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.ORCID 0000-0002-8717-9458
Aroob M AlromihMedical School, Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.ORCID 0000-0001-6146-7382
Emadeldin M ElsokkaryPsychology, Organisation Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.
Ali Z AldaliDepartment of Rehabilitation Health Science-Physical Therapy, College of Applied Medical Sciences, King Saud University, Riyadh 11445, Saudi Arabia.
Abdullah AlmezinyMedical School, Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.ORCID 0000-0001-5421-7852
Imam Mohammad ibn Saud Islamic University · SAKing Saud bin Abdulaziz University for Health Sciences · SAKing Saud University · SAUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Kingdom of Saudi Arabia was one of the countries earliest affected by the coronavirus 2019 (COVID-19) pandemic and had taken precautions including compulsory COVID-19 vaccination. Both the ChAdOx1 nCoV-19 vaccine (Oxford AstraZeneca) and the BNT162b2 vaccine (Pfizer) were approved by the Saudi Ministry of Health, followed by mRNA-1273 (Moderna), all of which were used for population-wide vaccination. This study aimed to assess the short-term side effects following the COVID-19 vaccinations among participants who had received all three doses in the western region of Saudi Arabia. An online survey was distributed to the participants who received either BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273 vaccines, and the type of side effects and their severity were evaluated. Fatigue and headache, pain at the site of the injection and muscle pain were the most common side effects in all three doses. However, the severity depending on the type of vaccination was significant only for the first and second dose, but not the third dose. In contrast, there was a higher percentage of participants who encountered severe side effects from the third dose compared to the first and second. Nevertheless, the majority of participants described all three doses' side effects to be moderately severe. A future evaluation could be made to access the individual types of vaccination and compare between the side effects of the BNT162b2, ChAdOx1 nCoV-19, and mRNA-1273 vaccines specifically for the booster dose.

Indexed as

adverse eventscoronavirusCOVID-19infectious diseasesvaccines

Identifiers

PMID36851144
PMCPMC9959497
OpenAlexW4318206240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.